Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures

Seizure

Volumn 8, Issue 2, 1999, Pages 120-127

  Petroff, Ognen A C ^a   Rothman, Douglas L ^b   Behar, Kevin L ^a   Hyder, Fahmeed ^b   Mattson, Richard H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

1H nuclear magnetic resonance spectroscopy; Epilepsy; Glutamate; Glutamine; Human; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; GLUTAMIC ACID; GLUTAMINE; PHENYTOIN; VALPROIC ACID;

ADULT; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERAMMONEMIA; MALE; OCCIPITAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0033118779     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.1999.0267     Document Type: Article

References (55)

1. Mattson, R.H., Cramer, J.A. and Collins, J.F. department of veterans affairs epilepsy cooperative study no 118 group. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 1985; 313: 145- 151.
2. Mattson, R.H., Cramer, J.A. and Collins, J.F. Department of veterans affairs epilepsy cooperative study no 264 group. A comparison of valproate with carbamazepine for the treatment of partial seizures and secondarily generalized tonic-clonic seizures in adults. New England Journal of Medicine 1992; 327: 765-771.
3. Löscher, W. and Schmidt, D. Strategies in antiepileptic drug development: Is rational drug design superiorto random screening and structural variation? Epilepsy Research 1994; 17: 95-134.
4. th Edition (Eds R.H. Levy, R.H. Mattson and B.S. Meldrum). New York, Raven Press, 1995: pp. 61-77.
5. Wood, J.H., Hare, T.A., Glaeser, B.S., Ballenger, J.C. and Post, R.M. Low cerebrospinal fluid γ -aminobutyric acid content in seizure patients. Neurology 1979; 29: 1203-1208.
6. Crawford, P.M. and Chadwick, D.W. GABA and amino acid concentrations in lumbar CSF in patients with treated and untreated epilepsy. Epilepsy Research 1987; 1: 328-338.
7. Petroff, O.A.C., Rothman, D.L., Behar, K.L. and Mattson, R.H. Low brain GABA level is associated with poor seizure control. Annals of Neurology 1996; 40: 908-911.
8. Godin, Y., Heiner, L., Mark, J. and Mandel, P. Effects of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. Journal of Neurochemistry 1969; 16: 869-873.
9. Cotariu, D., Zaidman, J.L. and Evans, S. Neurophysiological and biochemical changes evokedby valprotic acid in the central nervous system. Progress in Neurobiology 1990; 34: 343-354.
10. Löscher, W Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochemistry Research 1993; 18: 485- 502.
11. th Edition (Eds R.H. Levy, R.H. Mattson and B.S. Meldrum). New York, Raven Press, 1995: pp. 581-588.
12. Löscher, W and Siemes, H. Cerebrospinal fluid γ -aminobutyric acid levels in children with different types of epilepsy: Effect of anticonvulsant treatment. Epilepsia 1985; 26: 314-319.
13. Araki, K., Harada, M., Ueda, Y, Takino, T. and Kuryama, K. Alteration of amino acid content of cerebrospinal fluid from patients with epilepsy. Acta Neurologica Scandinavica 1988; 78: 473-479.
14. Pitkänen, A., Matilainen, R., Halonen, T., Kutvonen, R., Hartikainen, O. and Riekkinen, P. Inhibitory and excitatory amino acids in cerebrospinal fluid of chronic epileptic patients. Journal of Neurological Transmission 1989; 76: 221-230.
15. Nutt, J., Williams, A., Plotkin, C., Eng, N., Zeigler, M. and Calne, D.B. Treatment of Parkinson's disease with sodium valproate: Clinical, pharmacological, and biochemical observations. Canadian Journal of Neurological Science 1979; 6: 337-343.
16. Lautin, A., Angrist, B., Stanley, M., Gershon, S., Heckl, K. and Karobath, M. Sodium valproate in schizophrenia: Some biochemical correlates. British Journal of Psychiatry 1980; 137: 240-244.
17. Löscher, W and Hörstermann, D. Differential effects of vigabatrin, γ -acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn-Schmiedeberg's Archives of Pharmacology 1994; 349: 270-278.
18. Patsalos, P.N. and Lascelles, P.T. Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with the anticonvulsant drugs diphenylhydantoin, phenobarbitone, sodium valproate, ethosuximide, and sulthiamine in the rat. Journal of Neurochemistry 1981; 36:688-695.
19. Kapetanovic, I.M., Yonekawa, W.D., Torchin, C.D. and Kupferberg, H.J. Effects of pharmacological manipulations on basal and newly synthesized levels of GABA, glutamate, aspartate, and glutamine in mouse brain cortex. Biochemical Pharmacology 1988; 37: 4445-4449.
20. Valin, A., Voltz, C., Naquet, R. and Lloyd, K.G. Effects of pharmacological manipulation on neurotransmitter and other amino acid levels in the CSF of the senegalese baboon papio papio. Brain Research 1991; 538: 15-23.
21. Jaeken, J., Casaer, P. and Corbeel, L. Valproate increases cerebrospinal fluid glutamine levels. European Journal of Pediatrics 1987; 146: 91.
22. 1H NMR measurements of glutamate in the human brain. Magnetic Resonance in Medicine 1992; 25: 94-106.
23. 1H NMR measurements of GABA levels in human brain in vivo. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 5662-5666.
24. 1H spectroscopic measurements of GABA, glutamate, and glutamine in human brain. Epilepsia 1995; 36: 457-464.
25. Petroff, O.A.C. and Rothman, D.L. Measuring human brain GABA in vivo: Effects of GABA-transaminase inhibition. Molecular Neurobiology 1998; 16: 97-121.
26. Gruetter, R. Automatic localized in vivo adjustment of all first-and second-order shim coils. Magnetic Resonance in Medicine 1993; 29: 804-811.
27. 1H NMR spectra of human brain. Magnetic Resonance in Medicine 1994; 32: 294- 302.
28. Provencher, S.W. Estimation of metabolite concentrations from localized in vivo NMR spectra. Magnetic Resonance in Medicine 1993; 30: 672-679.
29. 13C glucose. Journal of Neurochemistry 1994; 63: 1377-1385.
30. Rothman, D.L., Behar, K.L., Prichard, J.W. and Petroff, O.A.C. Homocarnosine and the measurement of neuronal pH in patients with epilepsy. Magnetic Resonance in Medicine 1997; 32: 924-929.
31. Gardner, M.J. and Altman, D.G. Statistics with Confidence. London, BMJ Press, 1989.
32. Petroff, O.A.C., Rothman, D.L., Behar, K.L., Lamoureux, D. and Mattson, R.H. Initial observations on the effect of gabapentin on brain GABA in patients with epilepsy. Annals of Neurology 1996; 39: 95-99.
33. Petroff, O.A.C., Rothman, D.L., Behar, K.L., Collins, T.L. and Mattson, R.H. human brain GABA levels rise rapidly following initiation of vigabatrin therapy. Neurology 1996; 47: 1567- 1571.
34. Petroff, O.A.C., Hyder, R, Rothman, D.L. and Mattson, R.H. Human occipital lobe GABA and homocarnosine increased after starting topiramate. Neurology 1998; 50 (Suppl. 4): A312.
35. Kocsis, J.D. and Mattson, R.H. GABA levels in the brain: A target for new antiepileptic drugs. Neuroscientist 1996; 6:326- 334.
36. Hetherington, H.P., Kuzniecky, R.I. and Pan, J.W. Acute and chronic alternations in human cerebral GABA levels in response to topiramate, lamotrigine, and gabapentin. In: Proceedings of the International Society of Magnetic Resonance in Medicine, Vol. 1. Berkeley, International Society of Magnetic Resonance in Medicine, 1998: p. 542.
37. 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 2699-2704.
38. 15n n.m.r. Measurement of the in vivo rate of glutamine synthesis and utilization at steady state in the brain of the hyperammonaemic rat. Biochemical Journal 1993; 293: 461-468.
39. 15N heteronuclear multiple- Quantum coherence-transfer NMR. Biochemical Journal 1995; 311: 681-688.
40. th Edition (Eds R.H. Levy, R.H. Mattson and B.S. Meldrum). New York, Raven Press, 1995: pp. 641-648.
41. Warter, J.M., Brandt, C., Marescaux, C. et al. The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology 1983; 33: 1136-1140.
42. Batshaw, M.L. and Brusilow, S.W. Valproate-induced hyperammonemia. Annals of Neurology 1982; 11: 319-321.
43. Honeycutt, D., Callahan, K., Rutledge, L. and Evans, B. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 1992; 42: 666-668.
44. Perry, T.L., Hansen, S. and Maclean, J. Cerebrospinal fluid and plasma glutamine elevation by anticonvulsant drugs: A potential diagnostic and therapeutic trap. Clinica Chimica Acta 1976; 69: 441-445.
45. Sherwin, A.L., van Gelder, N.M. Amino acid and catecholamine markers of metabolic abnormalities in human focal epilepsy. Advances in Neurology 1986; 44: 1011-1032.
46. Perry, T. Cerebral amino acid pools. In: Handbook of Neurochemistry (Second Edition) Vol 1. (Ed. A. Lajtha). New York, Plenum Press, 1982: pp 151-180.
47. Petroff, O.A.C., Pleban, L.A. and Spencer, D.D. Symbiosis between in vivo and in vitro NMR spectroscopy: The creatine, N-acetylaspartate, glutamate, and GABA content of epileptic human brain. Magnetic Resonance Imaging 1995; 13: 1197- 1211.
48. Olsen, R.W. and Avoli, M. GABA and epileptogenesis. Epilepsia 1997; 38: 399-407.
49. Ottersen, O.P., Zhang, N. and Walberg, F. Metabolic compartmentation of glutamate and glutamine: Morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience 1992; 46: 519-534.
50. Conti, F. and Minelli, A. Glutamate immunoreactivity in rate cerebral cortex is reversibly abolished by 6-diazo-5-oxo-l- norleucine (DON), an inhibitor of phosphate-activated glutaminase. Journal of Histochemistry and Cytochemistry 1994; 42: 717-726.
51. Dejong, C.H.C., Deutz, N.E.P. and Soeters, P.B. Ammonia and glutamine metabolism during liver insufficiency: The role of kidney and brain in interorgan nitrogen exchange. Scandinavian Journal of Gastroenteritis 1996; 218: 61-77.
52. Sibson, N.R., Dhankhar, A., Mason, G.F., Rothman, D.L. Behar, K.L. and Shulman, R.G. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 316-321.
53. Peng, L., Hertz, L. and Huang, R. et al. Utilization of glutamine and TCA cycle constituents as precursors for transmitter glutamate and GABA. Dev Neurosci 1993; 15: 367-377.
54. Mignotte, B. and Vayssiere, J.L. Mitochondria and apoptosis. European Journal of Biochemistry 1998; 252: 1-15.
55. 15N nuclear magnetic resonance. Biochemical Journal 1995; 305: 329-336.